Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors. One executive’s patent cliff is another executive’s lucrative exit. German pharmaceutical giant Merck revealed Wednesday that it’s paying $6.7 billion for Terns Pharmaceuticals, as it tries to bridge a multibillion-dollar gap when its bestselling Keytruda comes off patent. Sign up for The Daily Upside at no cost for premium analysis on all your favorite stocks. READ ALSO: Lawsuit Losing S ...